Hypera Sa S/Adr (HYPMY) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen. Welcome to Ipera Pharma's earnings call for the fourth quarter of 2024. We have with us Mr. Breno Oliveira, CEO, Ramon Silva, CFO, and Adomario Couto, IRO. This event is being recorded. The video can be seen at the company's investor relations website, ri.ipera.com.br. We would also like to inform you that all participants will be in listen-only mode. We will then have a Q&A session. Further instructions will be given at this time. Before we proceed, I would like to reinforce that some information in this conference call may contain projections or statements about future expectations. This information is subject to known and unknown risks and uncertainties that may cause them not to materialize or to be substantially different from what was expected. I will now turn it over to Mr. Breno Oliveira, who will begin the presentation. Mr. Oliveira, you have the floor. Good morning. I'd like to thank you all for being here for our earnings presentation. I will start. Speaking about our growth on slide three, our sellout went up 9% in 2024 in the institutional non retail market. It was 26% in the retail market. It was 8%. We are continuing to grow significantly in the non retail market. It was nearly 20 percentage points above the overall market growth, and this was mainly driven by acceleration in sales for our current portfolio. Retail sellout growth was in line with our expectations for the year. Influenza medication, which is about one third of our sellout, had a significant recovery in the second half of the year, and concluded with a growth of 6% throughout the year versus a drop of 3% in 2023. Our growth was below the average market growth due to the mix effect and also due to a strong increase in the patented medication market, whi...